A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Phase 2 Terminated 14 enrolled Vertex Pharmaceuticals Incorporated

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study evaluates the efficacy and safety of VX-864 in participants with the PiZZ genotype over 48 weeks.

Timeline

Start: 2023-02-23
Primary completion: 2024-08-19
Completion: 2024-08-19

Outcome

Outcome not reported

Stopped: “Study drug dosing was permanently discontinued at the Sponsor's discretion based on frequency and nature of skin and subcutaneous tissue disorders.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-864	Unknown	—	Oral

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Summary

Timeline

Outcome

Drugs

Indications